Results Healthcare   |   Results International

Insights

We add value by understanding our sectors inside out, and release regular industry research and reports

UCB has divested the rights to 3 nitrate products in Europe and other selected markets to Merus Labs

By Kevin Bottomley

TORONTO, ONTARIO — FEBRUARY 1, 2016

Merus Labs, a Canada-based pharmaceutical company, announced today that it has entered into an agreement with Belgium-based UCB to acquire rights to Elantan, Isoket and Deponit in Europe and select other markets. Results Healthcare is delighted to have acted as exclusive advisors to UCB on this divestment process.

These products belong to a category of pharmaceuticals called nitrates, and are used to treat both acute and chronic coronary artery disease. “This transformational acquisition is a major step forward in our strategy to acquire important established medicines and leverage our scalable commercial platform,” stated Barry Fishman, Chief Executive Officer. “These essential products expand our presence in the cardiovascular market, materially increase our revenues, and significantly improve our cash flow”.

Acquisition Benefits

  • Established prescription products with proven safety and efficacy, predictable future cash flows, and no patent cliff.
  • Leverages existing commercial platform, with over 80 percent of revenue in countries where Merus’ existing products are currently sold.
  • Products are currently sold in 20 European countries plus Mexico, Turkey and South Korea.
  • A variety of formats are available, including tablet, spray, patch and injectable presentations.
  • An opportunity exists to launch the products in certain new markets and to expand formulations in existing markets.

Transaction Highlights

  • Merus has agreed to acquire product rights for a one-time payment of €92 million or 2.7 times last 12 months net revenue of approximately €34 million.
  • At current exchange rates, the products are expected to generate approximately $22 million in annual EBITDA.
  • On an annualized basis, the new products are expected to increase our existing products adjusted EBITDA by approximately 70 percent.
  • The acquisition will be funded with cash-on-hand and a new Euro-denominated five year term debt facility (matching where the majority of the product revenue will occur) at an interest rate of 4.5 percent per annum, decreasing as the Company de-leverages.
  • All conditions to closing under the purchase agreement, other than payment of the purchase price have been satisfied, and payment of the purchase price and closing are anticipated to be completed during the next five business days.

Amended and Restated Credit Facility

  • The new Euro-denominated term debt facility was advanced under an amendment and restatement to the Company’s existing credit agreement.
  • Pursuant to the terms of the amended credit agreement, the lenders agreed to provide senior secured credit facilities in the aggregate amount of $180 million, including a senior secured revolving credit facility in the principal amount of $10 million and senior secured term facilities in the aggregate principal amount of $170 million.
  • All of the Company’s obligations under the amended facility are guaranteed by all material subsidiaries of the Company and are secured by the material assets of the Company and the assets of, and all equity interests in its material subsidiaries.
  • The Company has converted the outstanding debt owing under the original credit agreement entered into in September 2014 into the Euro-denominated term debt facility.

 

To discover how Results Healthcare can work with you, please contact Kevin Bottomley or Max O’Connell.

Kevin Bottomley

Partner

Contact Kevin

Insights

Weekly Public Healthcare Sector Analysis, News, Blogs & White Papers

View our insights

Connect with us

Follow Results Healthcare on Twitter Follow Results Healthcare on LinkedIn

Your Nearest Office